ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2414

Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

Jolien van Nimwegen1, Esther Mossel 1, Robin Wijnsma 1, Greetje van Zuiden 1, Konstantina Delli 1, Alja Stel 1, Bert van der vegt 1, Erlin Haacke 1, Lisette Olie 1, Leonie Los 1, Gwenny Verstappen 1, Sarah Pringle 1, Fred Spijkervet 1, Frans Kroese 1, Arjan Vissink 1, Suzanne Arends 2 and Hendrika Bootsma 3, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, 3University of Groningen, Groningen, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: abatacept and treatment, randomized trials, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase III (ASAPIII) trial assessed the efficacy and safety of treatment with subcutaneous abatacept in patients with early active primary Sjögren’s syndrome (pSS). In the double blind phase, no difference was found in the primary endpoint, EULAR Sjögren’s syndrome disease activity score (ESSDAI) after 24 weeks, but a higher number of patients receiving abatacept reached the minimal clinically important change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI). B-cell hyperactivity was decreased by abatacept. The aim of the current analysis is to evaluate efficacy and safety of extended treatment with abatacept after 48 weeks.

Methods: The ASAP-III study is a monocenter, investigator-initiated, double-blind, placebo-controlled trial with an open label extension phase (NCT02067910). ASAP-III included 80 adult patients with biopsy-proven pSS, fulfilling the AECG and ACR/EULAR criteria, with a disease duration of ≤7 years and moderate to high (ESSDAI ≥5). After receiving weekly subcutaneous injections with abatacept (125 mg) or placebo for 24 weeks, all patients were treated with abatacept for another 24 weeks (figure 1). Concomitant use of other DMARDs including hydroxychloroquine was not permitted, with the exception of a stable dose of prednisone (≤10mg), and rescue therapy with prednisone or cyclophosphamide. At each visit (see figure 1), participants were evaluated by a multidisciplinary team of rheumatologists, ophthalmologists, and oral and maxillofacial surgeons. The primary endpoint was ESSDAI at 24 weeks. Secondary outcomes at 24 and 48 weeks included clinical, patient reported, functional, histological, laboratory, ultrasound, and microbiome parameters, and the occurrence of (serious) adverse events and treatment discontinuation.

Results: Patient characteristics at baseline and in week 24 are shown in table 1. Of 80 included patients, 78 were included in the extension phase. Two patients from the placebo arm were lost to follow up before week 24. Database lock for the extension phase is planned in September 2019. Subsequently, the first analyses of the week 24-48 results will be performed, focusing on ESSDAI, ESSPRI, quality of life (EQ-5D-5L), unstimulated and stimulated whole salivary flow (UWS, SWS), Schirmer’s test, Ocular Staining Score (OSS), serological parameters (rheumatoid factor, IgG), and safety parameters.

Conclusion: The ASAP-III trial was designed to assess the clinical efficacy and safety of subcutaneous abatacept in pSS patients with short disease duration and active disease. Results of week 24-48, the open-label extension phase, are available at the ACR 2019 annual meeting.

Figure 1: Design of the ASAPIII study.


Disclosure: J. van Nimwegen, Bristol-Myers Squibb, 5, 8; E. Mossel, None; R. Wijnsma, None; G. van Zuiden, Roche, 8; K. Delli, None; A. Stel, None; B. van der vegt, None; E. Haacke, None; L. Olie, None; L. Los, None; G. Verstappen, None; S. Pringle, None; F. Spijkervet, None; F. Kroese, Bristol-Myers Squibb, 2, 5, 8, Janssen-Cilag, 8, Roche, 8; A. Vissink, None; S. Arends, None; H. Bootsma, Bristol-Myers Squibb, 2, 5, 8, GlaxoSmithKline, 2, 5, HarmonicSS, 2, MedImmune, 2, 5, Medimmune, 5, Novartis, 5, 8, Roche, 2, 5, UCB, 2, 5, Union Chimique Belge, 5.

To cite this abstract in AMA style:

van Nimwegen J, Mossel E, Wijnsma R, van Zuiden G, Delli K, Stel A, van der vegt B, Haacke E, Olie L, Los L, Verstappen G, Pringle S, Spijkervet F, Kroese F, Vissink A, Arends S, Bootsma H. Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-abatacept-in-patients-with-early-active-primary-sjogrens-syndrome-open-label-extension-phase-of-a-randomized-controlled-phase-iii-trial/. Accessed May 19, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-abatacept-in-patients-with-early-active-primary-sjogrens-syndrome-open-label-extension-phase-of-a-randomized-controlled-phase-iii-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.